PALO ALTO, Calif., Dec. 08, 2023 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 05, 2023, the.
- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary
BridgeBio Pharma Announces Submission of New Drug globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
- As previously announced, the primary endpoint was met with a highly statistically significant p-value - The placebo and acoramidis time-to-first event Kaplan-Meier curves for a composite of.
- As previously announced, the primary endpoint was met with a highly statistically significant p-value - The placebo and acoramidis time-to-first event Kaplan-Meier curves for a composite of.